Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study

Publication | Closed Access

DOI

399

Citations

References

2016

Year

Yehuda Carmeli, J. Armstrong, Peter J. Laud, Paul Newell, Greg Stone, Angela Wardman, Leanne B. Gasink

The Lancet Infectious Diseases

Urinary Tract InfectionsUrologyAntimicrobial SusceptibilityAntibioticsBest Available TherapyHealthcare-associated InfectionVaginitisAntimicrobial TherapyMicrobiologyInfection ControlMedicineClinical MicrobiologyAntimicrobial ResistanceCeftazidime-resistant Enterobacteriaceae